ASCO Presentations on PGx Melanoma Drugs Portend Crowded Market for BRAF-Mutated Tumors | GenomeWeb

Originally published June 5.

CHICAGO – Roche's personalized melanoma drug Zelboraf (vemurafenib) – the first BRAF inhibitor to enter the market and one of the few drugs to significantly improve survival in patients with advanced disease – is likely to face significant competition in coming years from next-generation agents that will attempt to mirror or improve upon the agent's efficacy and safety against skin cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.